Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase IIa Randomized, Double Blind, Placebo Controlled, Multiple Dose Study on ABX464 in Combination With Methotrexate (MTX), in Patients With Moderate to Severe Active Rheumatoid Arthritis Who Have Inadequate Response to MTX or/and to Anti-Tnfα, or Intolerance to Anti-Tnfα

NCT03813199 is registered in ClinicalTrials.gov with Abivax S.A. as lead sponsor.

NCT NCT03813199
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03813199 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase IIa Randomized, Double Blind, Placebo Controlled, Multiple Dose Study on ABX464 in Combination With Methotrexate (MTX), in Patients With Moderate to Severe Active Rheumatoid Arthritis Who Have Inadequate Response to MTX or/and to Anti-Tnfα, or Intolerance to Anti-Tnfα
Lead sponsor
Abivax S.A.
Phase
Phase 2
Overall status
Completed
Start date
July 4, 2019
Completion date
April 27, 2021
Enrollment
60 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis